Table 4 Patient characteristics and outcome between those with advanced lung cancer inflammation index ALI score <18 (more inflammation) and those with ALI score > 18 (less inflammation) at the time of diagnosis
Variable | ALI < 18 (n = 83) (%) | ALI ≥ 18 (n = 90) (%) | P = value |
|---|---|---|---|
Age (median) | 56 | 58 | 0.26 (a) |
Male | 57 (69) | 59 (65) | 0.74 (b) |
AA | 42 (51) | 48 (53) | 0.76 (b) |
Adenocarcinoma | 51 (61) | 53 (59) | 0.75 (b) |
PS 2-4 | 27 (32) | 15 (17) | 0.02 (b) |
No chemotherapy | 41 (49) | 18 (20) | <0.001 (b) |
>2 metastatic sites | 48 (58) | 32 (35) | 0.003 (b) |
Response to chemotherapy | 15 (18%) | 50 (56%) | <0.0001(b) |
Median PFS | 2.4 | 5.1 | <0.001 (c) |
Median OS | 3.4 | 8.3 | <0.001 (c) |